Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up

Autor: Jan-Erik Palmgren, Vesa Kataja, Päivi Auvinen, K. Vuolukka, Sirpa Aaltomaa
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Oncology
Cancer Research
medicine.medical_specialty
Neoplasms
Radiation-Induced
medicine.medical_treatment
Brachytherapy
lcsh:RC254-282
030218 nuclear medicine & medical imaging
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Risk Factors
Surgical oncology
Internal medicine
Genetics
Humans
Medicine
Risk factor
Finland
Aged
Retrospective Studies
business.industry
Subsequent primary cancer
Incidence
Incidence (epidemiology)
Mortality rate
Low dose-rate brachytherapy
Prostatic Neoplasms
Neoplasms
Second Primary
Radiotherapy Dosage
Middle Aged
Prognosis
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Low-Dose Rate Brachytherapy
Radiation induced subsequent primary cancer
Survival Rate
Radiation therapy
030220 oncology & carcinogenesis
business
Follow-Up Studies
Research Article
Zdroj: BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020)
BMC Cancer
ISSN: 1471-2407
Popis: Background As aging is the most significant risk factor for cancer development, long-term prostate cancer (PCa) survivors have an evident risk of developing subsequent primary cancers (SPCs). Radiotherapy itself is an additional risk factor for cancer development and the SPCs appearing beyond 5 years after radiotherapy in the original treatment field can be considered as radiation-induced subsequent primary cancers (RISPCs). Methods During the years 1999-2008, 241 patients with localized PCa who underwent low dose-rate brachytherapy (LDR-BT) with I125 and were followed-up in Kuopio University Hospital, were included in this study. In this study the incidences and types of SPCs and RISPCs with a very long follow-up time after LDR-BT were evaluated. Results During the median follow-up time of 11.4 years, a total of 34 (14.1%) patients developed a metachronous SPC. The most abundant SPCs were lung and colorectal cancers, each diagnosed in six patients (16.7% out of all SPCs). The crude incidence rate of RISPC was 1.7% (n = 4). Half of the SPC cases (50%) were diagnosed during the latter half of the follow-up time as the risk to develop an SPC continued throughout the whole follow-up time with the actuarial 10-year SPC rate of 7.0%. The crude death rates due to metachronous out-of-field SPCs and RISPCs were 50 and 50%, respectively. Conclusion The crude rate of SPC was in line with previously published data and the incidence of RISPC was very low. These results support the role of LDR-BT as a safe treatment option for patients with localized PCa.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje